Eric Lefkofsky

Cofounder, Tempus

Search every verified Eric Lefkofsky interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Eric Lefkofsky, cofounder and CEO of Tempus, announced on July 20, 2026, that Tempus had entered into a definitive agreement to acquire Personalis. During a conference call, Lefkofsky stated that the acquisition was motivated by the belief that Personalis would quickly become a healthy business from a gross profit and margin perspective, and that Tempus intended to remain financially disciplined. He described the minimal residual disease (MRD) market as a $20 billion-plus opportunity and one of the fastest-growing segments in oncology diagnostics, while also noting that Tempus aimed to be EVA and free cash flow positive in 2027 even with the acquisition. At Tempus’s inaugural Investor Day on May 29, 2026, Lefkofsky said the company was founded ten years ago to use artificial intelligence to unlock precision medicine, requiring both proprietary data and a distribution system. He argued that data and AI will inevitably permeate drug discovery and healthcare, and predicted that no phase 3 clinical trials would ever fail in the future. Lefkofsky also described a vision in which real-world data insights would be layered onto every therapeutically relevant biomarker, and characterized Tempus’s ecosystem as sustainable, generating data from the clinical workflow and feeding insights back into the healthcare system.